Georgi Kapitanov 8/31/26 Georgi Kapitanov 8/31/26

The value of MBMA for determining best-in-class

Why Model-Based Meta-Analysis is one of the most useful tools for determining whether a drug pathway has hit its ceiling — and whether a best-in-class molecule is still achievable before you invest in optimization.

Georgi Kapitanov 8/17/26 Georgi Kapitanov 8/17/26

Target occupancy — how you define it can make or break your drug

Why 100% target occupancy can be misleading for soluble targets — total target accumulation reflects binding, not the free-target reduction that actually drives therapeutic effect, and how the two can diverge based on complex vs. target half-life.

Georgi Kapitanov 8/10/26 Georgi Kapitanov 8/10/26

Kd ≠ IC50

Why Kd and IC50 aren't interchangeable — a real case where two molecules looked equivalent in one binding assay and 3x different in another, and how target concentration relative to Kd explains why.

Georgi Kapitanov 8/3/26 Georgi Kapitanov 8/3/26

Translating biologics PK from preclinical species to humans

A practical breakdown of the approaches for translating biologics PK from preclinical species to humans — from full PBPK to minimal and site-of-action models — and how to pick the right one for your program.